J.W., a 48 year old First Nation male, telephoned the clinic and put his name forward in order to be considered for upcoming clinical trials. He had heard about ElectroTrichoGenesis treatment through a friend. Prior to acceptance to the clinical trial, the subject was required to visit the clinic. A registered nurse took his medical history and established hair loss type to ensure that it fell within the criteria set for the trial.

On his first visit to the clinic a medical history was taken and it was noted that this subject was healthy and not under a doctor's care. His past medical history was unremarkable. His height and weight were taken and recorded, as well as noting that he was not taking any prescription or non-prescription drugs, and had not tried any other hair loss products. He estimated his life stress factor as 5 (1 being low and 10 being high).

On examination, his scalp appeared healthy and his hair color was identified as black. On enquiry, the client stated that his hair loss had been gradual over the last eight years and he noticed the loss occurring mainly from the crown. His hair loss pattern, using the Hamilton Scale, was recorded as III Vertex. No one else in his family suffered from hair loss.

The client was then given some information and requirements pertaining to the trial. He was informed that hair care requirements consisted of daily shampooing of the hair using a mild shampoo and to use no mousses, hair sprays on the days that hair counts would be done, the first one being on his next visit. The treatment schedule was then explained to the client and it was impressed upon him that a regular weekly attendance was mandatory except for weeks 1 & 2 and 17 & 18 when two treatments per week were required. During the 33-week cycle an absence of only four treatments was permissible otherwise the client would be dropped from the clinical trial.

On reviewing the above information, the client satisfied the requirements for the clinical trial and therefore was instructed to return to the clinic two weeks later to be enrolled in the clinical trial. At that time a case record form was prepared for the client establishing his treatment schedule and in which all details of his attendance would be recorded as well as vital signs and hair counts. On week one of the treatment schedule, prior to giving treatment, vital signs were taken and recorded and it was established that his health had remained good and that no new medications were being taken. A consent form was signed and then a hair count was taken using a template with a pre-punched 1cm2 square and the first hair count was recorded as 107 hairs. To define this area on future occasions, two tattoo dots were placed in diagonally opposing corners of the previously defined square.

The twelve-minute treatment was given to the client and once the treatment was over a tentative day was established for the following treatment. He was reminded that at treatment days of weeks 8, 16, 24 and 33 quantification by way of hair counts would be taken as well as the vital signs and health history. In addition at week 33 quantification by patient evaluation would be part of the process. A constant watch was kept for any adverse effects but this client did not experience any. He did on occasion notice a tingling sensation while taking treatments, but this did not cause him distress.

The client attended very regularly throughout the 33-week period. At the 33 week evaluation, the client commented that his shedding had decreased, his hair was thicker and the overall appearance of his hair had improved. He noted all of this had occurred by week 26.

The client has continued treatments and has now been coming to the clinic for about two years. He remains very satisfied, his hair counts have now increased by 40% and in addition to the above he has stated that he would recommend this treatment to friends with a similar problem.

Michael A. Koss, M.D.
Corporate Clinic Director